Sexual Health Issues in Women with Cancer

Journal of Sexual Medicine

Volumn 10, Issue SUPPL., 2013, Pages 5-15

  Krychman, Michael ^a,b,c   Millheiser, Leah S ^d  

^a Southern California Center for Sexual Health and Survivorship Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Sexual health; Women

Indexed keywords

ALPHA TOCOPHEROL; AMFEBUTAMONE; ANASTROZOLE; ESTRADIOL; EXEMESTANE; HYALURONIC ACID; KAVA; LETROZOLE; LUBRICATING AGENT; OSPEMIFENE; PLACEBO; POLYCARBOPHIL; PRIMROSE OIL; TAMOXIFEN; TESTOSTERONE;

ARTICLE; ATROPHIC VAGINITIS; BLOOD CLOTTING DISORDER; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVOR; CANCER THERAPY; CLINICAL PRACTICE; DIARRHEA; DYSPAREUNIA; GYNECOLOGIC CANCER; HEALTH CARE; HEALTH CARE ACCESS; HORMONAL THERAPY; HUMAN; MORBIDITY; NAUSEA; PRIORITY JOURNAL; SEXUAL AROUSAL; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUAL HEALTH; SEXUAL INTEREST; SOCIAL PSYCHOLOGY; SOCIOLOGY; VAGINA ATROPHY; VAGINA DISCHARGE; VAGINAL DRYNESS; VAGINAL LUBRICATION; WOMEN'S HEALTH;

EID: 84873431567     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12034     Document Type: Article

References (63)

1. American Cancer Society. Cancer Facts and Figures. 2012. Atlanta, GA.
2. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: Understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998;16:501-14.
3. Schover L, etal. Sexual problems. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and practice of oncology. 5th edition. Philadelphia, PA: Lippincott-Raven Publishers; 1997:2857-72.
4. Ganz P, Desmond K, Belin TR, Meyerowitz BE, Rowland JH. Predictors of sexual health in women after a breast cancer diagnosis. J Clin Orthod 1999;17:2371-80.
5. Abbott-Anderson K, Kwekkeboom KL. A systematic review of sexual concerns reported by gynecological cancer survivors. Gynecol Oncol 2012;124:477-89.
6. Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: A systematic review. J Natl Cancer Inst 2012;104:386-405.
7. Avis NE, Crawford S, Manuel J. Psychosocial problems among younger women with breast cancer. Psychooncology 2004;13:295-308.
8. Fobair P, Stewart SL, Chang S, D'Onofrio C, Banks PJ, Bloom JR. Body image and sexual problems in young women with breast cancer. Psychooncology 2006;15:579-94.
9. Hawkins Y, Ussher J, Gilbert E, Perz J, Sandoval M, Sundquist K. Changes in sexuality and intimacy after the diagnosis and treatment of cancer: The experience of partners in a sexual relationship with a person with cancer. Cancer Nurs 2009;32:271-80.
10. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-29.
11. Graziottin A, Serafini A. HPV infection in women: Psychosexual impact of genital warts and intraepithelial lesions. J Sex Med 2009;6:633-45.
12. Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: A literature review. Psychooncology 2008;17:317-28.
13. Schover LR. Sexuality and body image in younger women with breast cancer. J Natl Cancer Inst Monogr 1994;16:177-82.
14. Burwell SR, Case LD, Kaelin C, Avis NE. Sexual problems in younger women after breast cancer surgery. J Clin Orthod 2006;24:2815-21.
15. Jensen PT, Groenvold M, Klee MC, Thranov I, Petersen MA, Machin D. Early stage cervical carcinoma, radical hysterectomy and sexual function. A longitudinal study. Cancer 2004;100:97-106.
16. Ceccaroni M, Roviglione G, Spagnolo E, Casadio P, Clarizia R, Peiretti M, Bruni F, Peters I, Aletti G. Pelvic dysfunctions and quality of life after nerve-sparing radical hysterectomy: A multicenter comparative study. Anticancer Res 2012;32:581-8.
17. Song T, Choi CH, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS. Sexual function after surgery for early-stage cervical cancer: Is there a difference in it according to the extent of surgical radicality? J Sex Med 2012;9:1697-704.
18. Aerts L, Enzlin P, Vergote I, Verhaeghe J, Poppe W, Amant F. Sexual, psychological, and relational functioning in women after surgical treatment for vulvar malignancy: A literature review. J Sex Med 2012;9:361-71.
19. Hazewinkel MH, Laan ET, Sprangers MA, Fons G, Burger MP, Roovers JP. Long-term sexual function in survivors of vulvar cancer: A cross-sectional study. Gynecol Oncol 2012;126:87-92.
20. El-Bahnasawy MS, Osman Y, El-Hefnawy A, Hafez A, Abdel-Latif M, Mosbah A, Ali-Eldin B, Shaaban AA. Radical cystectomy and urinary diversion in women: Impact on sexual function. Scand J Urol Nephrol 2011;45:332-8.
21. Elzevier HW, Nieuwkamer BB, Pelger RC, Lycklama a Nijeholt AA. Female sexual function and activity following cystectomy and continent urinary tract diversion for benign indications: A clinical pilot study and review of literature. J Sex Med 2007;4:406-16.
22. Traa MJ, De Vries J, Roukema JA, Den Oudsten BL. Sexual (dys)function and the quality of sexual life in patients with colorectal cancer: A systemic review. Ann Oncol 2012;23:19-27.
23. How P, Stelzner S, Branagan G, Bundy K, Chandrakumaran K, Heald RJ, Moran B. Comparative quality of life in patients following abdominoperineal excision and low anterior resection for low rectal cancer. Dis Colon Rectum 2012;55:400-6.
24. Rodrigues AC, Teixeira R, Teixeira T, Conde S, Soares P, Torgal I. Impact of pelvic radiotherapy on female sexuality. Arch Gynecol Obstet 2012;285:505-14.
25. Lange MM, Marijnen CA, Maas CP, Putter H, Rutten HJ, Stiggelbout AM, Meershoek-Klein Kranenbarg E, van de Velde CJ; Cooperative clinical investigators of the Dutch. Risk factors for sexual dysfunction after rectal cancer treatment. Eur J Cancer 2009;45:1578-88.
26. Brand AH. Vaginal stenosis in patients treated with radiotherapy for carcinoma of the cervix. Int J Gynecol Cancer 2006;16:288-93.
27. Jensen PT, Groenvold M, Klee MC, Thranov I, Petersen MA, Machin D. Longitudinal study of sexual function and vaginal changes after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 2003;56:937-49.
28. Watson M, Wheatley K, Harrison GA, Zittoun R, Gray RG, Goldstone AH, Burnett AK. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogenic or autologous, compared with consolidation chemotherapy alone: Analysis of the MRC AML 10 trial. Cancer 1999;86:1231-9.
29. Derzko C, Elliott S, Lam W. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol 2007;14(suppl 1):S20-40.
30. Panjari M, Bell RJ, Davis SR. Sexual function after breast cancer. J Sex Med 2011;8:294-302.
31. Kaplan HS. A neglected issue: The sexual side effects of current treatments for breast cancer. J Sex Marital Ther 1992;18:3-19.
32. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. J Clin Orthod 2004;22:4261-71.
33. Mortimer J, Boucher L, Baty J, Knapp D, Ryan E, Rowland J. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Orthod 1999;17:1488-92.
34. Auchincloss S and McCartney C. Gynecologic cancer. In: Holland J, ed. Psychoncology. New York: Oxford University Press; 1998:359-70.
35. Casey C. Psychosexual morbidity following gynecological malignancy. Ir Med J 1996;89:200-2.
36. Elliot SL, Stevenson RD. Chapter 11: Sexuality and illness. In: Leiblum SR, ed. Practices and principles of sex therapy. New York, NY: Guilford Press; 2007:314-49.
37. Bachman G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L, Goldstein I, Guay A, Leiblum S, Lobo R, Notelovitz M, Rosen R, Sarrel P, Sherwin B, Simon J, Simpson E, Shifren J, Spark R, Traish A; Princeton. Female androgen insufficiency: The Princeton consensus statement on definition, classification and assessment. Fertil Steril 2002;77:660-5, review.
38. Utian WH. Definitive symptoms of post menopause-incorporating use of vaginal parabasal cell index. Front Horm Res 1975;3:74-93.
39. Sarrel PM. Sexuality and menopause. Obstet Gynecol 1990;75:265-305.
40. Sarrel PM, Wiita B. Vasodilator effects of estrogen are not diminished by androgen in postmenopausal women. Fertil Steril 1997;68:1125-7.
41. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009;16:907-22.
42. Gennari L. Ospemifene hormos. Curr Opin Investig Drugs 2004;5:448-55 and (Eeva-Marja Rutanen, Jorma Heikkinen, Kaija Halonen, Jane Komi, Riots Lammintausta, and Olavi Ylikorkala. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: A double-blind, randomized trial. Menopause 10(5): 433-9).
43. Bachmann GA, Komi J, Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: Results from a pivotal phase 3 study. Menopause 2010;17:480-6.
44. Vagifem®[package insert]. Denmark: Novo Nordisk A/S; 2003.
45. Memorial Sloan-Kettering Cancer Center Clinical Trial. Serum estradiol levels in post menopausal women with breast cancer receiving adjuvant aromatase inhibitors and vaginal estrogen. NCT00984300. 2009. Available at: http://www.ClinicalTrials.gov (accessed September 26, 2010).
46. Kingsberg SA, Kellogg S, Krychman M. Treating dyspareunia caused by vaginal atrophy: A review of treatment options using vaginal estrogen therapy. Int J Womens Health 2009;2:1-6.
47. Rioux JE, Devlin MC, Gelfand MM, Steinberg WM, Hepburn DS. 17 beta estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7:156-61.
48. Loprinzi CL, Abu-Ghazaieh S, Sloan JA, vanHaelst-Pisani C, Hammer AH, Rowand KM Jr, Law M, Windschitl HE, Kaur JS, Ellison N. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997;15:969-73.
49. Ekin M, Yaşar L, Savan K, Temur M, Uhri M, Gencer I, Kivanç E. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: A randomized controlled trial. Arch Gynecol Obstet 2011;283:539-43.
50. Costantino D, Guaraldi C. Effectiveness and safety of vaginal suppositories for the treatment of the vaginal atrophy in postmenopausal women: An open, non-controlled clinical trial. Eur Rev Med Pharmacol Sci 2008;12:411-6.
51. Lee YK, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: A randomized controlled trial. Obstet Gynecol 2011;117:922-7.
52. Hutchison H, Kingsberg S, Krychman M, Schwartz P, Leiblum S, Rosen R, Althof S. A positive approach to female sexual health: A summary report. Female Patient 2009;34(4 Suppl 2):S1-6.
53. Carter J, Goldfrank D, Schover L. Simple strategies for vaginal health promotion in cancer survivors. J Sex Med 2011;8:549-59.
54. American College of Obstetricians and Gynecologists Task Force on Hormone Therapy. Sexual dysfunction. Obstet Gynecol 2004;104:85S-91S.
55. Mann E, Smith MJ, Hellier J, Balabanovic JA, Hamed H, Grunfeld EA, Hunter MS. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): A randomised controlled trial. Lancet Oncol 2012;13:309-18.
56. Seagraves R, Clayton A, Croft H, Wolf A, Warnock J. Bupropion sustained release for the treatment of hypoactive desire disorder. J Clin Psychopharmacol 2004;24:339-42.
57. Basson R, McInnes R, Smith MD, Hodgson G, Koppiker N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002;4:367-77.
58. Shifren JL, Davis SR, Dennerstein L, Heiman JR, Lobo RA, Simon JA, Kessel B, Gorodeski GI, Richardson MK, Rothert ML, Freedman RR, Gallagher JC, Henderson VW, Pinkerton JV, Reame NK, Simon JA, Speroff L, Schiff I, Utian WH. Position statement: The role of testosterone therapy in post menopausal women: A position statement of the North American Menopause Society. Menopause 2005;12:497-511.
59. Biosante website libigel data summary. 2012. Available at: http://www.biosante.com/libigel (accessed September 15, 2012).
60. Ito TY, Trant AS, Polan ML. A double-blind placebo-controlled study of ArginMax, a nutritional supplement for enhancement of female sexual function. J Sex Marital Ther 2001;27:541-9.
61. Ferguson D, Hosmane B, Heiman JR. Randomized, placebo-controlled, double-blind, parallel design trial of the efficacy and safety of Zestra® in women with mixed desire/interest/arousal/orgasm disorders. J Sex Marital Ther 2010;36:66-86.
62. Krychman ML, Kellogg S. A case series of female orgasmic complaints in cancer survivors treated with a topical applied blend of botanical oils and extracts. ISSM/SMSNA Cancer Survivorship and Sexuality Annual Meeting. Unmoderated Poster. Annual Meeting. Washington, DC. 2011.
63. Stausmire JM. Sexuality at the end of life. Am J Hosp Palliat Care 2004;21:33-9.